Ask about this productRelated genes to: IDH2 Blocking Peptide
- Gene:
- IDH2 NIH gene
- Name:
- isocitrate dehydrogenase (NADP(+)) 2, mitochondrial
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 15q26.1
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2019-04-23
Related products to: IDH2 Blocking Peptide
Related articles to: IDH2 Blocking Peptide
- Intramedullary spinal cord ependymomas are the most common intramedullary tumours in adults. However, clinical manifestation during pregnancy is exceptionally rare, and diagnosis may be delayed because pain, sensory disturbances, and muscle weakness are often mistakenly attributed to the common musculoskeletal changes associated with pregnancy. - Source: PubMed
Publication date: 2026/09/08
Kerimbayev Talgat TBorangaliyev DarynAbenov AzamatZhamoldin Daniyar KKadirbekov GalymzhanTuigynov ZhandosKenzhegulov YergenAleinikov Viktor GZhetpisbayev BerikUrunbayev YermekAbishev NurzhanOshayev MeirzhanNurperisov Aisa ZBaiturlin ZhanibekSolodovnikov MakarAkshulakov Serik K - Calcium oxalate (CaOx) crystal deposition is the major pathological process of kidney stone formation and causes renal tubular injury. However, the molecular mechanisms and metabolic alterations involved remain unclear. This study aimed to identify key molecules and pathways associated with CaOx crystal-induced renal injury. - Source: PubMed
Publication date: 2026/09/21
Xu YuexianHu DekaiZhang YunHou BingbingWang XingyuHao Zongyao - Acute myeloid leukemia (AML) is a heterogeneous disease with diverse genetic alterations that influence prognosis and treatment outcomes. Isocitrate dehydrogenase () genes, particularly and , have emerged as important prognostic biomarkers, but the impact of their mutations on survival remains controversial. This systematic review and meta-analysis aimed to evaluate the prognostic significance of mutations in AML, focusing on overall survival (OS) and relapse-free survival (RFS). A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science to identify eligible studies published up to February 2025. Studies reporting associations between mutations ( and ) and survival outcomes in AML were included. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted or derived when necessary. The analysis included 33 studies (n = 17,576). mutations were associated with improved overall survival (HR = 0.70, 95% CI: 0.63-0.78) and relapse-free survival (HR = 0.65, 95% CI: 0.52-0.82), particularly in patients treated with IDH inhibitors. mutations were associated with worse overall survival (HR = 1.16, 95% CI: 1.07-1.25) but showed no significant effect on relapse-free survival (HR = 1.03, 95% CI: 0.76-1.41). Subgroup analysis revealed a more favorable prognosis for R140 mutations, whereas R172 mutations showed heterogeneous outcomes across studies and treatment settings. mutations have a heterogeneous prognostic impact in AML, with mutations generally associated with better outcomes than mutations. Larger, well-designed studies with comprehensive molecular profiling are needed to further clarify their prognostic implications. - Source: PubMed
Ameli FereshtehAbdollahi AlirezaSalarvand SamanehGhasemi Dorsa - Pathogenic variants in the genes encoding isocitrate dehydrogenase (IDH1 and IDH2) are the defining driver mutations in diffuse low-grade gliomas. When IDH is mutated, the production of the oncometabolite 2-hydroxyglutarate triggers downstream metabolic changes that promote gliomagenesis. The identification of the isocitrate dehydrogenase mutation (mIDH) in diffuse gliomas has not only redefined prognosis but also treatment for patients with these tumours. With the identification of the IDH mutation, targeted therapies have emerged as a promising therapeutic strategy in gliomas. The INDIGO trial compared the IDH inhibitor vorasidenib to a placebo. Progression-free survival (PFS) and time to next intervention were extended in patients who received vorasidenib vs. placebo. The side-effect profile was tolerable compared to that of traditional cytotoxic chemotherapies. In August 2024, vorasidenib received FDA approval for the treatment of grade 2 mIDH gliomas and is included in the National Comprehensive Cancer Network Guidelines for central nervous system tumours. - Source: PubMed
Publication date: 2026/09/17
Bartman Kristin SPeters Katherine B - T-cell acute lymphoblastic leukemia (T-ALL) comprises molecularly diverse subtypes, but robust cross-cohort validations and operational gene-expression definitions are lacking. To establish a gene-expression-anchored framework for T-ALL subtyping, we aggregated 2314 transcriptomes (15 cohorts, age: 0.8-90.8 years). An extended unsupervised approach defined 17 main clusters and 3 subclusters in samples with high blast fractions. Supervised analyses added an overarching immature T-ALL (early T cell precursor [ETP]-like) definition and resolved the LMO2 γδ-like subtype. All clusters contained samples from at least two cohorts. Characteristic genomic driver enrichments were consistent across cohorts, while gene-expression clusters did not correspond exclusively to single driver events but also reflected developmental origins. A machine-learning classifier based on ALLCatchR, our B-cell acute lymphoblastic leukemia (B-ALL) classifier, identified these 20 transcriptomic subtypes and the immature T-ALL (ETP-like) signature with 0.995-1.0 accuracy in a validation set ( = 203). Testing the classifier on a second hold-out data set ( = 265 samples) showed that 92.7% of predictions matched with corresponding driver alterations. Across all samples, 83.2% of cases received high-confidence predictions, 7.3% candidate predictions, and 9.5% remained unclassified, largely because of low blast fractions. We identified a novel gene-expression cluster markedly enriched (P < 0.001) for clonal hematopoiesis mutations (, ) and a stem-/progenitor cell-like gene expression. This novel clonal hematopoiesis-related T-ALL subtype was observed in six cohorts and accounted for 8.9% of adults and 39.5% of patients aged >50 years. We extended ALLCatchR into ALLCatchR2, a free R package that now enables B-/T-lineage separation, gene-expression subtyping, blast estimation, and developmental annotation to harmonize T-ALL classification across studies and clinical contexts. - Source: PubMed
Publication date: 2026/09/14
Beder ThomasWolgast NadineWalter WenckeBendig SonjaHartmann Alina MBarz Malwine JZaliova MarketaReitzel Elisa-SophieBaden DavidSchwartz StefanGökbuget NicolaKester LennartTrka JanHaferlach ClaudiaBrüggemann MonikaBaldus Claudia DNeumann MartinBastian Lorenz